Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials

N Engl J Med. 2017 Apr 20;376(16):1504-1505. doi: 10.1056/NEJMp1615879.

Authors

Julia A Beaver¹, Gwynn Ison¹, Richard Pazdur¹

Affiliation

¹ From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research (J.A.B., G.I., R.P.) and the Oncology Center of Excellence (R.P.), Food and Drug Administration, Silver Spring, MD; and the Breast Cancer Program, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, DC (J.A.B.).

PMID: 28423289
DOI: 10.1056/NEJMp1615879

No abstract available

MeSH terms

Adult
Child
Clinical Trials as Topic / standards*
Eligibility Determination / standards
Humans
Neoplasms / therapy*
Patient Selection*